Escolà-Gil J C, Marzal-Casacuberta A, Julve-Gil J, Ishida B Y, Ordóñez-Llanos J, Chan L, González-Sastre F, Blanco-Vaca F
Servei de Bioquímica, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
J Lipid Res. 1998 Feb;39(2):457-62.
We report on the effect of human apolipoprotein (apo) A-II transgene expression on atherosclerosis susceptibility in two transgenic lines (25.3 and 11.1) whose plasma human apoA-II concentrations (approximately 23 and 96 mg/dl, respectively) span the normal range in humans. After 9 months of an atherogenic diet, 25.3 and 11.1 transgenic mice developed aortic atherosclerotic lesions that were approximately 1.7- and 7-fold, respectively, more extensive than those of non-transgenic control mice. However, there was no difference in the area of atherosclerosis of transgenic and control mice when fed a regular chow diet This contrasts with the findings in murine apoA-II transgenic mice and provides evidence of a species-specific characteristic that could be of relevance with respect to the high fat intake diets common in most industrialized countries. A possible mechanism of the pro-atherogenic action of human apoA-II could be the inhibition of reverse cholesterol transport and, in support of this, we observed an impairment of apoA-I-HDL particle interconversion in the plasma of 11.1 transgenic mice caused, at least in part, by a marked decrease in the endogenous lecithin:cholesterol acyltransferase activity.
我们报告了人载脂蛋白(apo)A-II转基因表达对两种转基因品系(25.3和11.1)动脉粥样硬化易感性的影响,这两种品系小鼠血浆中人apoA-II浓度(分别约为23和96mg/dl)涵盖了人类的正常范围。在致动脉粥样硬化饮食9个月后,25.3和11.1转基因小鼠主动脉粥样硬化病变分别比非转基因对照小鼠广泛约1.7倍和7倍。然而,当喂食常规饲料时,转基因小鼠和对照小鼠的动脉粥样硬化面积没有差异。这与鼠apoA-II转基因小鼠的研究结果形成对比,并提供了一种物种特异性特征的证据,这可能与大多数工业化国家常见的高脂肪摄入饮食有关。人apoA-II促动脉粥样硬化作用的一种可能机制可能是抑制胆固醇逆向转运,支持这一观点的是,我们观察到11.1转基因小鼠血浆中apoA-I-HDL颗粒相互转化受损,这至少部分是由内源性卵磷脂:胆固醇酰基转移酶活性显著降低所致。